4D-150 Intravitreal Gene Therapy: Phase II Data
Time: 12:00 pm
day: Conference Day One
Details:
- Understanding the advantages of intravitreal injection platform to appreciate superior delivery method over competing approaches
- Examining the safety of 4D-150 from the Phase II wet AMD trial to recognize breakthrough safety profiles in gene therapy
- Exploring the scientific evidence behind customized capsids to understand why 4DMT has solved safety challenges where nobody else has
